Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial

Additional reductions in low-density lipoprotein-cholesterol (LDL-C) via antidiabetic therapies should be considered in statin-using patients with sub-optimal LDL-C levels. We compared the efficacy of anagliptin and sitagliptin, two antidiabetic therapies, in reducing LDL-C in type 2 diabetic patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Morimoto, Takeshi, Sakuma, Ichiro, Sakuma, Mio, Tokushige, Akihiro, Natsuaki, Masahiro, Asahi, Tomohiro, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Node, Koichi, Ueda, Shinichiro
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561974/
https://ncbi.nlm.nih.gov/pubmed/31189978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-44885-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados